About Arvinas Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.arvinas.com/
Frequently Asked Questions
What is the 52-week range for ARVN?
The 52-week high is $14.51 and the 52-week low is $6.97.
What is the P/E ratio for ARVN?
The Price to Earnings (P/E) ratio is 52.27.
What is the dividend yield for ARVN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 1.91%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 2.94%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.76.
Analyst Recommendation Trends
Wall Street analyst consensus for ARVN over the last few months:
Latest ARVN News
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
NEW HAVEN, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that novel biomarker data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease will be presented as late-breaking oral and poster presentations at the 2026 International Congress of Parkinson’s Disease and Movement Disorders® (MDS), taking place October 4-8, 2026,
Arvinas To Present Biomarker Data From Phase 1 Clinical Trial Of ARV-102 In Participants With Parkinson’s Disease At 2026 International Congress Of Parkinson’s Disease And Movement Disorders
Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that novel biomarker data from a Phase 1 clinical trial of ARV-102
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted an option to purchase 64,766 shares of common stock (the “Option Award”) and 42,388 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The Option Award and RSU Award were each granted as of September 28, 2026 (the “Gr
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors – NEW HAVEN, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the first participant has been dosed in its Phase 1/2 clinical trial of ARV-6723, an investigational, oral PROteolysis TArgeting Chimera (PROTAC)
Arvinas Q2 2026 Earnings Call Transcript
Arvinas (NASDAQ:ARVN) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings
Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?
Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Arvinas, Inc. (ARVN) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 9:15 AM EDTCompany ParticipantsRandy Teel - CEO, President...
AdvanCell Appoints Sean Cassidy as Chief Financial Officer
BOSTON & BRISBANE, Australia, September 15, 2026--AdvanCell Appoints Sean Cassidy as Chief Financial Officer
Arvinas (ARVN) Just Made Protein Degrader History With FDA Nod
On August 4, Arvinas Inc. (NASDAQ:ARVN) reported second-quarter 2026 financial results and a corporate update that doubled as one of the more consequential updates in the company’s history. The clinical-stage biotech disclosed the first-ever FDA approval of a PROTAC, a heterobifunctional protein degrader, alongside a licensing deal that hands off commercial duties to another drugmaker. […]
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-24 | Kennedy Edward Moore Jr. | +22,714 | - | - |
| 2026-06-24 | Kennedy Edward Moore Jr. | +15,527 | - | - |
| 2026-06-24 | Morrison Briggs | +22,714 | - | - |
| 2026-06-24 | Morrison Briggs | +15,527 | - | - |
| 2026-06-24 | Smaldone Alsup Laurie | +22,714 | - | - |
| 2026-06-24 | Smaldone Alsup Laurie | +15,527 | - | - |
| 2026-06-24 | Bain Linda | +22,714 | - | - |
| 2026-06-24 | Bain Linda | +15,527 | - | - |
| 2026-06-24 | Cunningham Everett | +22,714 | - | - |
| 2026-06-24 | Cunningham Everett | +15,527 | - | - |
| 2026-06-24 | Norwalk Leslie V | +22,714 | - | - |
| 2026-06-24 | Norwalk Leslie V | +15,527 | - | - |
| 2026-06-24 | Saik Andrew | -5,696 | $8.159 | $46,474 |
| 2026-06-17 | Cacace Angela M | -2,576 | $7.595 | $19,565 |
| 2026-05-21 | Teel Randy | -2,209 | $9.0365 | $19,962 |
| 2026-05-11 | Loomis David K | -1,919 | $9.9374 | $19,070 |
| 2026-05-11 | Cacace Angela M | -9,657 | $9.9374 | $95,965 |
| 2026-05-11 | Teel Randy | -9,657 | $9.9374 | $95,965 |
| 2026-05-11 | Saik Andrew | -11,139 | $9.9374 | $110,693 |
| 2026-05-11 | Berkowitz Noah | -11,108 | $9.9374 | $110,385 |
| 2026-03-18 | Berkowitz Noah | -6,435 | $11.1004 | $71,431 |
| 2026-03-06 | Morrison Briggs | +20,000 | $13.4035 | $268,070 |
| 2026-02-27 | Houston John G | -11,787 | $13.14 | $154,881 |
| 2026-02-27 | Houston John G | -18,822 | $13.24 | $249,203 |
| 2026-02-27 | Houston John G | -4,688 | $13.24 | $62,069 |
| 2026-02-26 | Teel Randy | +147,179 | - | - |
| 2026-02-26 | Loomis David K | +18,504 | - | - |
| 2026-02-26 | Loomis David K | +12,420 | - | - |
| 2026-02-26 | Cacace Angela M | +67,000 | - | - |
| 2026-02-26 | Cacace Angela M | +45,000 | - | - |
| 2026-02-26 | Teel Randy | +218,691 | - | - |
| 2026-02-26 | Teel Randy | +147,791 | - | - |
| 2026-02-26 | Saik Andrew | +67,000 | - | - |
| 2026-02-26 | Saik Andrew | +45,000 | - | - |
| 2026-02-26 | Berkowitz Noah | +67,000 | - | - |
| 2026-02-26 | Berkowitz Noah | +45,000 | - | - |
| 2026-02-23 | Loomis David K | -1,108 | $12.16 | $13,473 |
| 2026-02-23 | Cacace Angela M | -2,571 | $12.16 | $31,263 |
| 2026-02-23 | Cacace Angela M | -1,038 | $12.16 | $12,622 |
| 2026-02-23 | Teel Randy | -3,748 | $12.16 | $45,576 |
| 2026-02-23 | Teel Randy | -1,038 | $12.16 | $12,622 |
| 2026-02-13 | Teel Randy | -4,403 | $11.89 | $52,352 |
| 2026-02-13 | Cacace Angela M | -4,592 | $11.89 | $54,599 |
| 2026-02-13 | Loomis David K | -1,016 | $11.89 | $12,080 |
| 2026-02-13 | Saik Andrew | -5,134 | $11.89 | $61,043 |
| 2026-02-13 | Berkowitz Noah | -5,685 | $11.89 | $67,595 |
| 2025-11-07 | Loomis David K | -230 | $9.89 | $2,275 |